Ciphergen Biosystems, Inc. Conference Call and Webcast

Apr 25, 2001, 01:00 ET from Ciphergen Biosystems, Inc.

    FREMONT, Calif., April 25 /PRNewswire/ --
 Ciphergen Biosystems, Inc. (Nasdaq: CIPH) will announce its first quarter 2001
 financial results on Tuesday, May 1, after the market close.  The announcement
 will be followed by a conference call at 11:00 a.m. (EDT) on Wednesday, May 2,
 hosted by William E. Rich, President and Chief Executive Officer, and Matthew
 Hogan, Vice President and Chief Financial Officer.
     This call will be broadcast simultaneously via the Internet at
 www.ciphergen.com and will be accessible through the Investor Relations
 Section of Ciphergen Biosystems' homepage.  Please visit the web site at least
 15 minutes prior to the start of the call to allow time to register, download
 and install any necessary software.  A replay will be available on this site
 for 14 days.
     Additionally, a telephone replay of the teleconference will be available
 for 24 hours beginning at 2:30 (EDT) on Wednesday, May 2, and can be accessed
 by dialing Domestic:  800-475-6701 or International 320-365-3844, Access Code:
 581786.
     Ciphergen develops, manufactures and markets the ProteinChip(R) System
 that enables protein discovery, characterization and assay development to
 provide researchers with a better understanding of biological functions at the
 protein level.  The ProteinChip System is a novel, enabling tool in the
 emerging field of protein-based biology research, known as proteomics.
 Proteomics provides a direct approach to understanding the role of proteins in
 the biology of disease, monitoring of disease progression and the therapeutic
 effects of drugs.  Ciphergen believes Proteomics will be a major focus of
 biological research by enhancing the understanding of gene function and the
 molecular basis of disease.
     NOTE:  Ciphergen and ProteinChip are registered trademarks of Ciphergen
 Biosystems, Inc.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X08228183
 
 

SOURCE Ciphergen Biosystems, Inc.
    FREMONT, Calif., April 25 /PRNewswire/ --
 Ciphergen Biosystems, Inc. (Nasdaq: CIPH) will announce its first quarter 2001
 financial results on Tuesday, May 1, after the market close.  The announcement
 will be followed by a conference call at 11:00 a.m. (EDT) on Wednesday, May 2,
 hosted by William E. Rich, President and Chief Executive Officer, and Matthew
 Hogan, Vice President and Chief Financial Officer.
     This call will be broadcast simultaneously via the Internet at
 www.ciphergen.com and will be accessible through the Investor Relations
 Section of Ciphergen Biosystems' homepage.  Please visit the web site at least
 15 minutes prior to the start of the call to allow time to register, download
 and install any necessary software.  A replay will be available on this site
 for 14 days.
     Additionally, a telephone replay of the teleconference will be available
 for 24 hours beginning at 2:30 (EDT) on Wednesday, May 2, and can be accessed
 by dialing Domestic:  800-475-6701 or International 320-365-3844, Access Code:
 581786.
     Ciphergen develops, manufactures and markets the ProteinChip(R) System
 that enables protein discovery, characterization and assay development to
 provide researchers with a better understanding of biological functions at the
 protein level.  The ProteinChip System is a novel, enabling tool in the
 emerging field of protein-based biology research, known as proteomics.
 Proteomics provides a direct approach to understanding the role of proteins in
 the biology of disease, monitoring of disease progression and the therapeutic
 effects of drugs.  Ciphergen believes Proteomics will be a major focus of
 biological research by enhancing the understanding of gene function and the
 molecular basis of disease.
     NOTE:  Ciphergen and ProteinChip are registered trademarks of Ciphergen
 Biosystems, Inc.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X08228183
 
 SOURCE  Ciphergen Biosystems, Inc.